September #127 : Magnum PIs: Protease inhibitor bulletin

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Back to School

The Money Pit

Retro Virus

ONLINE EXCLUSIVE: Mixed Doubles




Old School

“C” Ya In Bed

Kick in the Butt

Dear Dairy

Magnum PIs: Protease inhibitor bulletin

Code Blueberry

The Porn Identity

Bye George!

Good, Dirty Fun

Deposit Slip




Blood Sport

United We Fall

U.S. Steal

A Capitol Punishment?

The Mourning Show

Crash

Hurts So Good




Editor’s Letter-Septmeber 2006

Mailbox-September 2006

Catch of the Month-September 2006



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

September 2006


Magnum PIs: Protease inhibitor bulletin

Prezista and Aptivus are the latest approved members of the protease inhibitor (PI) HIV med class. Like other PIs, these cut viral loads by preventing immune cells from making more HIV, and they require a Norvir (ritonavir) booster dose. But these two may knock out some HIV that’s grown PI-resistant.

  1. Prezista (darunavir, formerly TMC-114), which won FDA approval in June, controlled HIV with a twice-daily dose, even in those who’ve taken PIs before.
  2. Aptivus (tipranavir) was approved last year for those who’ve taken combos (including PIs) before. But recently, some Aptivus takers developed bleeding in the brain. While researchers locate the cause, Aptivus should be used cautiously by anyone with risk factors for excessive brain bleeding such as high blood pressure or use of blood thinners. Red flags are up, too, for those allergic to sulfa drugs (an Aptivus ingredient). The future of the PI for those new to HIV meds is hazy: In May, a study for treatment newcomers was halted when Aptivus with a 200 mg Norvir booster was found to be liver-unfriendly, while Aptivus plus 100 mg Norvir was ineffective.



[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    aqua_31206
    Macon
    Georgia


    july8th69
    brooklyn
    New York


    pevans
    San Francisco
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.